(Q57111038)

English

Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009

article

In more languages

Statements

scholarly article

0 references

Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009 (English)

0 references

1 reference

based on heuristic

inferred from title

World Health Organization

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Marie Paule Kieny

4

object named as

Marie Paule Kieny

0 references

Frederick G Hayden

1

object named as

Frederick G Hayden

0 references

author name string

Wendy A Howard

2

0 references

Laszlo Palkonyay

3

0 references

language of work or name

0 references

publication date

24 June 2009

0 references

0 references

27

0 references

31

0 references

4079-89

0 references

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials." World Health Organization, Geneva, Switzerland, 14-15 February 2008.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

A commercial ELISA detects high levels of human H5 antibody but cross-reacts with influenza A antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.04.059

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.04.059

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57111038&oldid=1953544759"